logo
NIT Rourkela study reveals health toll on parents of children with disabilities

NIT Rourkela study reveals health toll on parents of children with disabilities

India Today11-07-2025
A recent study by researchers at NIT Rourkela has brought attention to a pressing issue that often goes unnoticed, how raising children with developmental disabilities takes a serious toll on the physical and emotional well-being of parents, especially mothers.Led by Dr Ramakrishna Biswal, Associate Professor in the Department of Humanities and Social Sciences, along with senior research scholar Abhijit Pathak, the study explores how continuous caregiving can cause exhaustion, health problems, and emotional strain.advertisementTheir work was published in the Asia Pacific Journal of Social Work and Development.
Surveying over 400 parents of children with autism, ADHD, cerebral palsy, and multiple disabilities, the research found that the daily caregiving demands often lead to chronic headaches, fatigue, pain, ulcers, and a feeling of being emotionally worn out.The impact on physical health, the study shows, is not just a result of stress, it can also make stress harder to manage, creating a feedback loop that further weakens a caregiver's capacity.
STUDY URGES CAREGIVER SUPPORT FOR BETTER CHILD DISABILITY The researchers used the biopsychosocial model, which looks at how health is shaped by physical, psychological, and social forces together, not in isolation.Their findings reveal that while physical health is a key factor, financial pressures and social isolation also play major roles. Many parents, especially in India, struggle with stigma, lack of awareness, and minimal access to support services.Speaking on the findings, Dr Biswal said: 'Disability rights are increasingly recognised, but caregivers remain overlooked. Raising such children is not just a parental duty, it's a shared responsibility of the entire community.'The team recommends including caregiver health checks and stress support within paediatric disability services. They also suggest setting up community-based centres where families can access medical, mental, and financial help in one place.At its heart, the study sends a clear message: when caregivers are supported, children thrive. Without that, families are left to cope alone, and too often, they do so in silence.- Ends
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues
Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Business Standard

time4 days ago

  • Business Standard

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues
Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Time of India

time4 days ago

  • Time of India

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Domestic drug majors Sun Pharma , Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator . As per the latest Enforcement Report of US Food and Drug Administration ( USFDA), ), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Explore courses from Top Institutes in Please select course: Select a Course Category PGDM Operations Management MBA others Data Analytics Cybersecurity Public Policy Management Healthcare Design Thinking MCA Data Science Data Science Product Management Others Artificial Intelligence Degree Project Management Digital Marketing Technology Leadership CXO healthcare Finance Skills you'll gain: Financial Analysis & Decision Making Quantitative & Analytical Skills Organizational Management & Leadership Innovation & Entrepreneurship Duration: 24 Months IMI Delhi Post Graduate Diploma in Management (Online) Starts on Sep 1, 2024 Get Details Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How Much Does It Cost to Rent a Private Jet - The Prices May Surprise You! Private Jet I Search Ads Learn More Undo The medication is used to treat attention deficit hyperactivity disorder ( ADHD ). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Live Events Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy 's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories , Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharma, Lupin, Dr Reddys recall products in US market
Sun Pharma, Lupin, Dr Reddys recall products in US market

News18

time4 days ago

  • News18

Sun Pharma, Lupin, Dr Reddys recall products in US market

New Delhi, Jul 27 (PTI) Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to 'Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to 'Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. PTI MSS HVA view comments First Published: July 27, 2025, 10:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store